Specific targeting of adriamycin conjuga
โ
Ruth Adler; Esther Hurwitz; Jack R. Wands; Michael Sela; Daniel Shouval
๐
Article
๐
1995
๐
John Wiley and Sons
๐
English
โ 741 KB
Doxorubicin (adriamycin), once considered the treatment of choice for hepatocellular carcinoma (HCC), is known to cause cardiotoxicity and myelotoxicity. To reduce the systemic toxicity of adriamycin by direct delivery of the drug to the tumor site, we established a panel of monoclonal antibodies (M